Lucid Diagnostics Inc. (LUCD) key performance indicators and operating metrics (8 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| EsoGuard Revenue | 1.3M | FY2026-Q1 |
| Non-GAAP Adjusted Loss Per Common Share | -0.07 USD_per_share | FY2026-Q1 |
| Non-GAAP Adjusted Loss | 10.5M | FY2026-Q1 |
| Operating Expenses | 13.4M | FY2026-Q1 |
| EsoGuard Esophageal DNA Tests Processed | 3.66K | FY2025-Q4 |
| GAAP Earnings per Common Share | 0.12 USD_per_share | FY2025-Q4 |
| Stock-Based Compensation Expenses | 1.2M | FY2025-Q4 |
| Total Operating Expenses | 13M | FY2025-Q3 |
Back to LUCD overview · LUCD earnings · LUCD holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.